BTSG on Nasdaq
BrightSpring Health Services, Inc.
In its 2026 annual report the company says: “We are a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. We have a differentiated approach to care delivery, with an integrated and scaled model that addresses critical services that the highest-need and highest-cost patients require.”5 It is headquartered in Louisville, Kentucky.1 Its shares trade on Nasdaq under the symbol BTSG.1
$60.86 down 1.50 (2.41%)Price as of Oct 16, 2026 at 19:58 UTC
Last updated Oct 21, 2026.
Overview
Compare with Option Care Health, Inc., AdaptHealth Corp. or Chemed Corporation, or pick any stock.
- TickerBTSG on Nasdaq1
- IndustryServices-Home Health Care Services1
- HeadquartersLouisville, Kentucky1
- Incorporated inDE3
- Business address805 N. Whittington Parkway, Louisville, Ky 402223
- Filer categoryLarge accelerated filer3
- Legal formCorporation
See how the biggest companies compare on our leaderboards
We are a leading home and community-based healthcare services platform, focused on delivering complementary pharmacy and provider services to complex patients. We have a differentiated approach to care delivery, with an integrated and scaled model that addresses critical services that the highest-need and highest-cost patients require. With a focus on Senior and Specialty patients, which includes Behavioral populations, our platform provides pharmacy and provider services (both clinical and supportive care in nature) in lower-cost home and community settings largely to Medicare, Medicaid, and commercially-insured populations. We are an essential part of our nation’s health delivery network as a front-line provider of high-quality and cost-effective care to a large and growing number of people, who increasingly require a combination of specialized solutions to enable holistic health care …5 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
11.8%Gross margin6
2.3%Operating margin6
1.5%Net margin6
28.2%Revenue growth, 20256
10.2%Return on equity6
1.31×Debt to equity6
$394.7MFree cash flow6
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Medicare D brought in 32% of the revenue BrightSpring Health Services, Inc. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Medicare D | $2.0B | $3.2B | $4.1B |
| Commercial Insurance | $1.8B | $2.5B | $3.3B |
| Medicare C | $1.5B | $1.7B | $2.4B |
| Medicaid | $979.1M | $1.2B | $1.5B |
| Medicare A | $958.6M | $999.6M | $1.1B |
| Private and Other | $378.0M | $415.1M | $424.1M |
| Medicare B | $82.8M | $95.9M | $82.8M |
Business segments
Pharmacy Solutions brought in 89% of the revenue BrightSpring Health Services, Inc. broke down this way in fiscal 2025.
Business segments by year
| Business segments | 2023 | 2024 | 2025 |
|---|---|---|---|
| Pharmacy Solutions | $6.5B | $8.8B | $11.4B |
| Provider Services | $1.2B | $1.3B | $1.5B |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Selling, general and admin9¢$1.2B
- Other costs88¢$11.3B
- Interest1¢$157.3M
- Income tax0¢$33.1M
- Profit1¢$190.7M
Out of $12.9B in revenue.6
Where each dollar of operating cash went, fiscal 2025
- Capital spending19¢$95.5M
- Share buybacks9¢$43.2M
- Kept or used elsewhere72¢$351.5M
Out of $490.2M of cash from operations.6
Financial statements
Every line of the income statement as filed: the last 4 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total revenues | $12.9B | $10.1B | $7.7B | |
| Cost of goods | $10.5B | $8.0B | $5.8B | |
| Cost of services | $885.4M | $797.3M | $711.3M | |
| Gross profit | $1.5B | $1.3B | $1.1B | |
| Selling, general, and administrative expenses | $1.2B | $1.2B | $1.1B | |
| Operating income | $295.3M | $108.0M | $58.1M | |
| Loss on extinguishment of debt | $12.7M | |||
| Interest expense, net | $157.3M | $190.5M | $271.9M | |
| Income (loss) from continuing operations before income taxes | $137.9M | -$95.3M | -$213.8M | |
| Income tax expense (benefit) | $33.1M | -$26.4M | -$31.5M | $33.1M |
| Net income (loss) from continuing operations | $104.8M | -$68.9M | -$182.3M | |
| Income from discontinued operations, net of income taxes | $84.3M | $48.4M | $25.4M | |
| Net income (loss) | $189.1M | -$20.5M | -$156.8M | |
| Net loss attributable to noncontrolling interests included in continuing operations | -$1.6M | -$2.5M | -$2.2M | |
| Net income (loss) attributable to BrightSpring Health Services, Inc. and subsidiaries | $190.7M | -$18.1M | -$154.6M | |
| Continuing operations | $1 | -$0 | -$2 | |
| Discontinued operations | $0 | $0 | $0 | |
| Net income (loss) per share | $0.94 | -$0.09 | -$1.31 | |
| Continuing operations | $0 | -$0 | -$2 | |
| Discontinued operations | $0 | $0 | $0 | |
| Net income (loss) per share | $0.87 | -$0.09 | -$1.31 | |
| Basic | 202.6M shares | 193.0M shares | 117.9M shares | |
| Diluted | 219.8M shares | 193.0M shares | 117.9M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $88.4M | $61.0M | ||
| Accounts receivable, net of allowance for credit losses | $989.7M | $902.8M | ||
| Inventories | $815.2M | $636.6M | ||
| Prepaid expenses and other current assets | $118.6M | $161.3M | ||
| Total current assets | $2.9B | $1.9B | ||
| Property and equipment, net of accumulated depreciation of $404,878 and $339,892 at December 31, 2025 and 2024, respectively | $204.7M | $180.6M | ||
| Goodwill | $2.5B | $2.4B | $2.3B | |
| Intangible assets, net of accumulated amortization | $557.6M | $595.2M | ||
| Operating lease right-of-use assets, net | $171.6M | $161.0M | ||
| Deferred income taxes, net | $0 | $5.3M | ||
| Other assets | $39.7M | $39.1M | ||
| Total assets | $6.4B | $5.9B | ||
| Trade accounts payable | $1.2B | $923.9M | ||
| Accrued expenses | $333.0M | $295.7M | ||
| Current portion of obligations under operating leases | $42.9M | $38.9M | ||
| Current portion of obligations under financing leases | $6.8M | $3.5M | ||
| Current portion of long-term debt | $52.3M | $48.7M | ||
| Total current liabilities | $1.8B | $1.4B | ||
| Obligations under operating leases, net of current portion | $135.4M | $129.5M | ||
| Obligations under financing leases, net of current portion | $14.5M | $6.5M | ||
| Long-term debt, net of current portion | $2.5B | $2.6B | ||
| Deferred income taxes, net | $6.2M | |||
| Long-term liabilities | $66.6M | $71.2M | ||
| Total liabilities | $4.5B | $4.3B | ||
| Redeemable noncontrolling interests | $11.2M | $3.7M | ||
| Common stock, $0.01 par value, 1,500,000,000 shares authorized, 192,124,125 and 174,245,990 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1.9M | $1.7M | ||
| Preferred stock, $0.01 par value, 250,000,000 authorized; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | |||
| Additional paid-in capital | $2.0B | $1.9B | ||
| Accumulated deficit | -$74.6M | -$222.2M | ||
| Accumulated other comprehensive (loss) income | -$6.7M | $1.4M | ||
| Total shareholders' equity | $1.9B | $1.6B | ||
| Noncontrolling interest | $74.0K | $0 | ||
| Total equity | $1.9B | $1.6B | $585.4M | $754.8M |
| Total liabilities, redeemable noncontrolling interests, and equity | $6.4B | $5.9B | ||
| Property and equipment, net of accumulated depreciation | $404.9M | $339.9M | ||
| Common Stock, par value | $0.01 | $0.01 | ||
| Common Stock, shares authorized | 1.5B shares | 1.5B shares | ||
| Common Stock, Shares, Issued | 192.1M shares | 174.2M shares | ||
| Common Stock, shares outstanding | 192.1M shares | 174.2M shares | ||
| Preferred Stock , par value | $0.01 | $0.01 | ||
| Preferred Stock, shares authorized | 250.0M shares | 250.0M shares | ||
| Preferred Stock, shares issued | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding | 0 shares | 0 shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $88.4M | $61.0M | ||
| Accounts receivable, net of allowance for credit losses | $989.7M | $902.8M | ||
| Inventories | $815.2M | $636.6M | ||
| Prepaid expenses and other current assets | $118.6M | $161.3M | ||
| Total current assets | $2.9B | $1.9B | ||
| Property and equipment, net of accumulated depreciation of $404,878 and $339,892 at December 31, 2025 and 2024, respectively | $204.7M | $180.6M | ||
| Goodwill | $2.5B | $2.4B | $2.3B | |
| Intangible assets, net of accumulated amortization | $557.6M | $595.2M | ||
| Operating lease right-of-use assets, net | $171.6M | $161.0M | ||
| Deferred income taxes, net | $0 | $5.3M | ||
| Other assets | $39.7M | $39.1M | ||
| Total assets | $6.4B | $5.9B | ||
| Trade accounts payable | $1.2B | $923.9M | ||
| Accrued expenses | $333.0M | $295.7M | ||
| Current portion of obligations under operating leases | $42.9M | $38.9M | ||
| Current portion of obligations under financing leases | $6.8M | $3.5M | ||
| Current portion of long-term debt | $52.3M | $48.7M | ||
| Total current liabilities | $1.8B | $1.4B | ||
| Obligations under operating leases, net of current portion | $135.4M | $129.5M | ||
| Obligations under financing leases, net of current portion | $14.5M | $6.5M | ||
| Long-term debt, net of current portion | $2.5B | $2.6B | ||
| Deferred income taxes, net | $6.2M | |||
| Long-term liabilities | $66.6M | $71.2M | ||
| Total liabilities | $4.5B | $4.3B | ||
| Redeemable noncontrolling interests | $11.2M | $3.7M | ||
| Common stock, $0.01 par value, 1,500,000,000 shares authorized, 192,124,125 and 174,245,990 shares issued and outstanding at December 31, 2025 and 2024, respectively | $1.9M | $1.7M | ||
| Preferred stock, $0.01 par value, 250,000,000 authorized; no shares issued and outstanding at December 31, 2025 and 2024 | $0 | |||
| Additional paid-in capital | $2.0B | $1.9B | ||
| Accumulated deficit | -$74.6M | -$222.2M | ||
| Accumulated other comprehensive (loss) income | -$6.7M | $1.4M | ||
| Total shareholders' equity | $1.9B | $1.6B | ||
| Noncontrolling interest | $74.0K | $0 | ||
| Total equity | $1.9B | $1.6B | $585.4M | $754.8M |
| Total liabilities, redeemable noncontrolling interests, and equity | $6.4B | $5.9B | ||
| Property and equipment, net of accumulated depreciation | $404.9M | $339.9M | ||
| Common Stock, par value | $0.01 | $0.01 | ||
| Common Stock, shares authorized | 1.5B shares | 1.5B shares | ||
| Common Stock, Shares, Issued | 192.1M shares | 174.2M shares | ||
| Common Stock, shares outstanding | 192.1M shares | 174.2M shares | ||
| Preferred Stock , par value | $0.01 | $0.01 | ||
| Preferred Stock, shares authorized | 250.0M shares | 250.0M shares | ||
| Preferred Stock, shares issued | 0 shares | 0 shares | ||
| Preferred Stock, shares outstanding | 0 shares | 0 shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.6
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $189.1M | -$20.5M | -$156.8M |
| Depreciation and amortization | $164.3M | $204.5M | $202.3M |
| Impairment of long-lived assets | $12.6M | $10.2M | $10.6M |
| Change in fair value of contingent consideration, net | -$1.3M | $2.3M | |
| Payment of contingent consideration in excess of acquisition date fair value | -$6.2M | -$2.4M | |
| Provision for credit losses | $56.2M | $34.0M | $23.2M |
| Amortization of deferred debt issuance costs | $11.2M | $12.1M | $20.9M |
| Share-based compensation | $70.1M | $69.2M | $3.9M |
| Deferred income taxes, net | $14.8M | -$25.9M | -$52.6M |
| Loss on extinguishment of debt | $12.7M | ||
| Loss on disposition of fixed assets | $2.1M | $101.0K | $349.0K |
| Other | -$4.4M | -$2.5M | -$572.0K |
| Accounts receivable | -$131.3M | -$179.0M | -$127.2M |
| Prepaid expenses and other current assets | $30.7M | $7.6M | -$34.9M |
| Inventories | -$177.9M | -$236.5M | $28.7M |
| Trade accounts payable | $264.2M | $303.2M | $105.6M |
| Accrued expenses | $32.0M | -$144.6M | $193.6M |
| Other assets and liabilities | -$36.2M | -$20.7M | -$6.4M |
| Net cash provided by operating activities | $490.2M | $23.8M | $210.8M |
| Purchases of property and equipment | -$95.5M | -$80.9M | -$73.5M |
| Acquisitions of businesses, net of cash acquired | -$204.6M | -$59.8M | -$63.1M |
| Other | -$5.0M | $473.0K | $2.2M |
| Net cash used in investing activities | -$305.1M | -$140.2M | -$134.4M |
| Long-term debt borrowings | $2.6B | ||
| Long-term debt repayments | -$50.3M | -$3.4B | -$30.4M |
| Proceeds from issuance of common stock on initial public offering, net | $656.5M | ||
| Proceeds from issuance of tangible equity units, net | $389.0M | ||
| (Repayments) borrowings of the Revolving Credit Facility, net | -$63.3M | $12.6M | -$24.1M |
| Payment of debt issuance costs | -$47.0M | ||
| Repurchase of shares of common stock | -$43.2M | -$650.0K | -$650.0K |
| Proceeds from shares issued under share-based compensation plan | $25.3M | $1.5M | $598.0K |
| Payment of taxes related to net share settlement of equity awards | -$7.6M | -$1.2M | |
| Repurchase of stock options | -$10.0M | ||
| Payment of contingent consideration up to acquisition date fair value | -$200.0K | -$1.8M | -$1.5M |
| Purchase of redeemable noncontrolling interest | -$5.1M | -$2.3M | |
| Investment in noncontrolling interests | $735.0K | ||
| Payment of financing lease obligations | -$13.5M | -$11.6M | -$11.6M |
| Net cash (used in) provided by financing activities | -$157.9M | $164.6M | -$76.9M |
| Net increase (decrease) in cash and cash equivalents | $27.2M | $48.2M | -$557.0K |
| Interest, net | $183.5M | $211.4M | $303.5M |
| Income taxes, net of refunds | $27.0M | $25.0M | $37.5M |
| Notes issued and contingent liabilities assumed in connection with acquisitions | $22.3M | $7.5M | |
| Financing lease obligations (Note 13) | $20.3M | $13.1M | $11.6M |
| Repurchases of common stock in accounts payable | $650.0K | ||
| Purchases of property and equipment in accounts payable | $6.8M | $12.1M | $13.0M |
| Acquisition consideration in accounts payable | $42.2M | $2.5M | |
| Consideration for purchase of redeemable noncontrolling interest in accounts payable | $5.1M | ||
| Shares issued in connection with acquisitions | $31.1M |
No quarter-by-quarter statement was filed.
Compare BrightSpring Health Services, Inc. with another company
Corporate structure
BrightSpring Health Services, Inc. sits at the top of its group. 9 entities, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of BrightSpring Health Services, Inc.
- FMR LLC Filed SCHEDULE 13G/A on BrightSpring Health Services, Inc., latest Aug 6, 2026 (6 filings since Oct 7, 2024)
- VANGUARD PORTFOLIO MANAGEMENT LLC Filed SCHEDULE 13G on BrightSpring Health Services, Inc., latest Jul 31, 2026
- BlackRock Filed SCHEDULE 13G/A on BrightSpring Health Services, Inc., latest Jul 27, 2026 (3 filings since Jan 21, 2026)
- KKR Phoenix Aggregator L.P. Filed SCHEDULE 13D/A on BrightSpring Health Services, Inc., latest Jun 5, 2026 (6 filings since Sep 18, 2024)
- VANGUARD GROUP INC Filed SCHEDULE 13G/A on BrightSpring Health Services, Inc., latest Mar 26, 2026 (3 filings since Jul 29, 2025)
- PRICE T ROWE ASSOCIATES INC /MD/ Filed SCHEDULE 13G on BrightSpring Health Services, Inc., latest Nov 14, 2025
- Invesco Filed SCHEDULE 13G on BrightSpring Health Services, Inc., latest Aug 7, 2025
- Walgreens Boots Alliance Filed SCHEDULE 13G/A on BrightSpring Health Services, Inc., latest May 14, 2025 (2 filings since Nov 14, 2024)
- NORGES BANK Filed SCHEDULE 13G/A on BrightSpring Health Services, Inc., latest Feb 10, 2025 (2 filings since Nov 8, 2024)
- BrightSpring Health Services, Inc. Louisville, Kentucky
- Abode Healthcare, Inc. Subsidiary · Delaware, United States
- BrightSpring Health Holdings Corp. Subsidiary · Delaware, United States
- OncoMed Specialty LLC Subsidiary · Delaware, United States
- Pharmacy Corporation of America Subsidiary · California, United States
- PharMerica Corporation Subsidiary · Delaware, United States
- PharMerica Drug Systems LLC Subsidiary · Delaware, United States
- PharMerica Institutional Pharmacy Services LLC Subsidiary · Delaware, United States
- Res-Care, Inc. Subsidiary · Kentucky, United States
Built from subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What BrightSpring Health Services, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $609.6M6 Dec 31, 2025 | $520.5M6 Dec 31, 2024 | +17.1% |
| Accumulated depreciation | $404.9M6 Dec 31, 2025 | $339.9M6 Dec 31, 2024 | +19.1% |
| Property and equipment, net | $204.7M6 Dec 31, 2025 | $180.6M6 Dec 31, 2024 | +13.4% |
| Operating-lease assets (leased space) | $171.6M6 Dec 31, 2025 | $161.0M6 Dec 31, 2024 | +6.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $88.4M6 Dec 31, 2025 | $61.0M6 Dec 31, 2024 | +45.0% |
| Stakes in other companies (equity method) | $721.0K6 Dec 31, 2025 | $420.0K6 Dec 31, 2024 | +71.7% |
Intangibles and goodwill
| Item | Latest | A year before | Change |
|---|---|---|---|
| Goodwill | $2.5B6 Dec 31, 2025 | $2.4B6 Dec 31, 2024 | +7.7% |
| Intangible assets, net (excluding goodwill) | $557.6M6 Dec 31, 2025 | $595.2M6 Dec 31, 2024 | −6.3% |
| Finite-lived intangibles, gross | $911.6M6 Dec 31, 2025 | $976.0M6 Dec 31, 2024 | −6.6% |
| Accumulated amortization | $547.3M6 Dec 31, 2025 | $516.4M6 Dec 31, 2024 | +6.0% |
| Finite-lived intangibles, net | $364.3M6 Dec 31, 2025 | $459.6M6 Dec 31, 2024 | −20.7% |
Inventory
Properties, in its own words
Our principal executive offices are located in Louisville, Kentucky, where we lease approximately 100,000 square feet. We also own 2 properties and lease 849 properties in the United States and lease one property in Canada. Of the leased properties, approximately 76% are provider service properties and 24% are pharmacy locations. We consider these facilities to be suitable and adequate for the management and operations of our business. Our properties that are associated with the Community Living business are excluded from this Item 2 since those operations are excluded from continuing operations.
Item 2 of the 10-K filed Feb 27, 2026.5
Leadership
Who has led BrightSpring Health Services, Inc., and when. Pick a name to see everywhere that person has worked.
Chief financial officer
2025
- PresidentScott A. Greenwell Jun 27, 2025 to now10
- PresidentJennifer Yowler Jan 26, 2024 to Jun 27, 202511
- Chief financial officerJennifer A. Phipps Jan 27, 2026 to now12
Board members and other officers (11)
- OfficerJames F. Mattingly Jr. Jan 26, 2024 to Jan 28, 202513
- Chief Accounting OfficerJennifer A. Phipps Jan 26, 2024 to now14
- OfficerLisa A. Nalley Jan 26, 2024 to now15
- OfficerMichael A. McMaude Jan 26, 2024 to now16
- OfficerSteven S. Reed Jan 26, 2024 to Jan 30, 202417
- Board memberNigam H. Shah Jun 12, 2026 to now18
- Board memberHunter H. Craig Jan 26, 2024 to Jan 26, 202419
- Board memberMatthew Dambrosio Jan 26, 2024 to May 21, 202420
- Board memberMax Lin Jan 26, 2024 to Jan 26, 202421
- Board memberOlivia F. Kirtley Jan 26, 2024 to now22
- Board memberTimothy A. Wicks Apr 30, 2024 to now23
Named in SEC Form D filings
People the company listed in its private-offering notices.
Subsidiaries and ownership
Subsidiaries (Exhibit 21)
- Abode Healthcare, Inc. Delaware4
- BrightSpring Health Holdings Corp. Delaware4
- OncoMed Specialty LLC Delaware4
- PharMerica Corporation Delaware4
- PharMerica Drug Systems LLC Delaware4
- PharMerica Institutional Pharmacy Services LLC Delaware4
- Pharmacy Corporation of America California4
- Res-Care, Inc. Kentucky4
The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.
Timeline
- Jul 31, 20268-K Results of operations25
- Jun 12, 20268-K Executive or director change; Regulation FD disclosure26
- Jun 5, 20268-K Entered a material agreement27
- May 21, 20268-K Shareholder vote28
- May 1, 20268-K Results of operations29
- Mar 31, 20268-K Completed an acquisition or sale; Executive or director change; Regulation FD disclosure30
- Mar 4, 20268-K Entered a material agreement31
- Feb 27, 20268-K Results of operations32
- Oct 28, 20258-K Results of operations33
- Oct 22, 20258-K Entered a material agreement34
- Oct 20, 20258-K Results of operations35
- Aug 1, 20258-K Results of operations36
Calendar
Coming up
- Oct 30, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $0.30 a share, on Oct 20, 2025.37
When it reported results
- Jul 31, 2026Reported quarterly or annual results25
- May 1, 2026Reported quarterly or annual results29
- Feb 27, 2026Reported quarterly or annual results32
- Oct 28, 2025Reported quarterly or annual results33
- Oct 20, 2025Reported quarterly or annual results35
- Aug 1, 2025Reported quarterly or annual results36
- May 2, 2025Reported quarterly or annual results38
- Mar 6, 2025Reported quarterly or annual results39
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
232 filings to the SEC since October 2021: 3 annual reports, 8 quarterly reports, 34 major events, 107 insider forms, 25 large holders, 1 private raises, 54 other. The latest 20:
- Sep 16, 20264 EDGAR
- Sep 14, 2026144 EDGAR
- Aug 6, 2026SCHEDULE 13G/A EDGAR
- Jul 31, 2026SCHEDULE 13G EDGAR
- Jul 31, 202610-Q EDGAR
- Jul 31, 20268-K EDGAR
- Jul 28, 20264 EDGAR
- Jul 27, 2026SCHEDULE 13G/A EDGAR
- Jun 22, 20264 EDGAR
- Jun 12, 20268-K EDGAR
- Jun 12, 20264 EDGAR
- Jun 12, 20263 EDGAR
- Jun 5, 2026424B7 EDGAR
- Jun 5, 20268-K EDGAR
- Jun 5, 2026SCHEDULE 13D/A EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
- Jun 5, 20264 EDGAR
The 232 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
36 open-market trades by officers, directors and large owners since October 2021: 10 buys and 26 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 14, 2026 | Greenwell Scott A.President, PharMerica | Sale | 15,099 | $57.91 | $874.4K | Form 4 |
| Jun 5, 2026 | KRAVIS HENRY R10% owner | Sale | 14,669,771 | $58.45 | $857.4M | Form 4 |
| Jun 5, 2026 | KKR Associates Americas XII L.P.10% owner | Sale | 14,669,771 | $58.45 | $857.4M | Form 4 |
| Jun 5, 2026 | ROUSSEAU JON BSee Remarks | Sale | 260,000 | $58.75 | $15.3M | Form 4 |
| Jun 5, 2026 | Nalley Lisa ASee Remarks | Sale | 35,000 | $58.75 | $2.1M | Form 4 |
| Jun 5, 2026 | Phipps Jennifer AChief Financial Officer | Sale | 35,000 | $58.75 | $2.1M | Form 4 |
| Mar 4, 2026 | KKR & Co. Inc.10% owner | Sale | 19,715,000 | $40.96 | $807.5M | Form 4 |
| Mar 4, 2026 | KKR Phoenix Aggregator GP LLC10% owner | Sale | 19,715,000 | $40.96 | $807.5M | Form 4 |
| Mar 4, 2026 | Nalley Lisa ASee Remarks | Sale | 30,000 | $41.15 | $1.2M | Form 4 |
| Mar 4, 2026 | ROUSSEAU JON BSee Remarks | Sale | 220,000 | $41.15 | $9.1M | Form 4 |
| Mar 4, 2026 | Phipps Jennifer AChief Financial Officer | Sale | 35,000 | $41.15 | $1.4M | Form 4 |
| Oct 22, 2025 | KRAVIS HENRY R10% owner | Sale | 14,745,000 | $28.78 | $424.4M | Form 4 |
| Oct 22, 2025 | KKR Americas XII Ltd10% owner | Sale | 14,745,000 | $28.78 | $424.4M | Form 4 |
| Oct 22, 2025 | ROUSSEAU JON BSee Remarks | Sale | 235,000 | $28.78 | $6.8M | Form 4 |
| Oct 22, 2025 | Nalley Lisa ASee Remarks | Sale | 20,000 | $28.78 | $575.6K | Form 4 |
| Jun 24, 2025 | KKR Group Co. Inc.10% owner | Sale | 2,100,000 | $21.15 | $44.4M | Form 4 |
| Jun 24, 2025 | KKR Phoenix Aggregator GP LLC10% owner | Sale | 2,100,000 | $21.15 | $44.4M | Form 4 |
| Jun 12, 2025 | KKR Group Partnership L.P.10% owner | Sale | 13,288,101 | $21.15 | $281.0M | Form 4 |
| Jun 12, 2025 | KKR Phoenix Aggregator L.P.10% owner | Sale | 13,288,101 | $21.15 | $281.0M | Form 4 |
| Jun 12, 2025 | Phipps Jennifer AChief Financial Officer | Sale | 15,616 | $21.75 | $339.6K | Form 4 |
All 36 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- FMR LLCSCHEDULE 13G/A, 6 filings Oct 7, 2024 to Aug 6, 202640
- VANGUARD PORTFOLIO MANAGEMENT LLCSCHEDULE 13G, 1 filing Jul 31, 202641
- BlackRockSCHEDULE 13G/A, 3 filings Jan 21, 2026 to Jul 27, 202642
- KKR Phoenix Aggregator L.P.SCHEDULE 13D/A, 6 filings Sep 18, 2024 to Jun 5, 202643
- VANGUARD GROUP INCSCHEDULE 13G/A, 3 filings Jul 29, 2025 to Mar 26, 202644
- PRICE T ROWE ASSOCIATES INC /MD/SCHEDULE 13G, 1 filing Nov 14, 202545
- InvescoSCHEDULE 13G, 1 filing Aug 7, 202546
- Walgreens Boots AllianceSCHEDULE 13G/A, 2 filings Nov 14, 2024 to May 14, 202547
- NORGES BANKSCHEDULE 13G/A, 2 filings Nov 8, 2024 to Feb 10, 202548
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Jon RousseauPresident and Chief Executive Officer | 52 | $17.8M49 | |
| 2025 | Jennifer PhippsExecutive Vice President and Chief Financial Officer | 45 | $4.4M49 | |
| 2025 | Lisa NalleyChief of Staff and Senior Vice President, Human Resource | 53 | $2.4M49 | |
| 2025 | Scott GreenwellExecutive Vice President and President, PharMerica | 49 | $1.4M49 | |
| 2025 | Jennifer YowlerFormer President, PharMerica and Senior Vice President, Sales and Account Management | $1.4M49 | ||
| 2025 | Bob BarnesPresident, Community Living | $1.1M49 | ||
| 2025 | Jim MattinglyFormer Executive Vice President and Chief Financial Officer | $543.5K49 | ||
| 2024 | Jon RousseauPresident and Chief Executive Officer | 52 | $17.7M49 | |
| 2024 | Jim MattinglyFormer Executive Vice President and Chief Financial Officer | $2.3M49 | ||
| 2024 | Lisa NalleyChief of Staff and Senior Vice President, Human Resource | 53 | $2.3M49 | |
| 2024 | Bob BarnesPresident, Community Living | $1.8M49 | ||
| 2023 | Jon RousseauPresident and Chief Executive Officer | 52 | $18.3M49 | |
| 2023 | Jim MattinglyFormer Executive Vice President and Chief Financial Officer | $909.0K49 | ||
| 2023 | Bob BarnesPresident, Community Living | $744.7K49 |
Money raised
Private offerings the company reported to the SEC on Form D.
- Sep 1, 2024Raised $30 million in a private offering of equity Form D: 1 investor so far Form D
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Kohlberg Kravis Roberts & Co. L.P. | 26,829,880 | $1.9B | 34.3% | −14,994,379 |
| BlackRock, Inc. | 24,027,537 | $1.7B | 0.0% | +4,425,378 |
| Fmr LLC | 13,393,155 | $934.0M | 0.0% | −7,585,378 |
| Invesco Ltd. | 11,942,017 | $832.8M | 0.1% | +459,861 |
| Vanguard Portfolio Management LLC | 9,946,458 | $693.7M | 0.0% | +1,913,688 |
| Vanguard Capital Management LLC | 7,312,566 | $510.0M | 0.0% | +1,016,820 |
| State Street Corp | 6,263,316 | $436.8M | 0.0% | +1,329,375 |
| Geode Capital Management, LLC | 5,183,124 | $375.9M | 0.0% | +1,618,171 |
| Manufacturers Life Insurance Company, The | 3,432,423 | $239.4M | 0.2% | −826,842 |
| Fuller & Thaler Asset Management, Inc. | 3,360,970 | $234.4M | 0.6% | +109,579 |
| American Century Companies Inc | 3,291,039 | $229.5M | 0.1% | New |
| Dimensional Fund Advisors LP | 2,738,751 | $191.0M | 0.0% | −154,028 |
| Alliancebernstein L.P. | 4,320,642 | $184.1M | 0.1% | +770,208 |
| Marshall Wace, Llp | 2,636,177 | $183.8M | 0.2% | −18,181 |
| Morgan Stanley | 2,167,944 | $151.2M | 0.0% | +1,103,929 |
| Arrowstreet Capital, Limited Partnership | 2,093,256 | $146.0M | 0.1% | +722,816 |
| Brown Advisory Inc | 1,958,436 | $136.6M | 0.2% | −208,289 |
| Norges Bank | 1,955,905 | $136.4M | 0.0% | New |
| Charles Schwab Investment Management Inc | 1,889,829 | $131.8M | 0.0% | +302,233 |
| Bank Of America Corp /de/ | 1,827,855 | $127.5M | 0.0% | +293,701 |
| Ameriprise Financial Inc | 1,798,601 | $125.5M | 0.0% | +438,378 |
| Farallon Capital Management, L.l.c. | 1,732,800 | $120.8M | 0.7% | +115,800 |
| Bank of New York Mellon Corp | 1,694,318 | $118.2M | 0.0% | +961,781 |
| Nuveen, LLC | 1,682,635 | $117.3M | 0.0% | +157,466 |
| Franklin Resources Inc | 1,678,416 | $117.1M | 0.0% | +415,128 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How BrightSpring Health Services, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARBrightSpring Health Services, Inc.1
- CIK0001865782
- Employer ID (EIN)82-29564045
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company5
- Incorporated inDelaware5
- Fiscal year endsDecember 311
- Industry code (SIC)8082 Services-Home Health Care Services1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address805 N. Whittington Parkway, Louisville, KY 402221
- Phone502-394-21001
- Shares outstanding197,864,241 as of Jul 28, 20269
- Public float$2.3B as of Jun 30, 20255
- AuditorKPMG LLP, Louisville, Kentucky PCAOB ID 185; it also attests to the company’s internal control over financial reporting5
- On EDGAR sinceJul 7, 20211
- Filings234 in all: 4 (85), 8-K (33), 3 (20), SCHEDULE 13G/A (11), 10-Q (8), 424B7 (8), S-1/A (6), 144 (5)1
All 33 form types
CORRESP (5), DRS/A (5), SCHEDULE 13D/A (5), SCHEDULE 13G (5), UPLOAD (4), 10-K (3), DEFA14A (3), DRSLTR (3), SC 13G (3), 4/A (2), 424B4 (2), ARS (2), DEF 14A (2), DRS (2), S-1 (2), 8-A12B (1), 8-K/A (1), CERT (1), D (1), EFFECT (1), FWP (1), RW (1), S-3ASR (1), S-8 (1), SC 13D (1)
- Latest filingsAnnual report (10-K) Feb 27, 2026
Quarterly report (10-Q) Jul 31, 2026
Proxy statement (DEF 14A) Apr 10, 2026
Latest 8-K (8-K) Jul 31, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.01 per share | BTSG | The Nasdaq Stock Market LLC |
| 6.75% Tangible Equity Units | BTSGU | The Nasdaq Stock Market LLC |
From the cover page of the 10-K filed Feb 27, 2026 (Section 12(b) of the Exchange Act).5
Risk factors and legal proceedings
The risks BrightSpring Health Services, Inc. names in Item 1A of its 10-K filed Feb 27, 2026: 55 risks under these headings, as written.5
- Risks Related to Our Business
- We operate in a highly competitive industry.
- If we are unable to maintain relationships with existing patient referral sources or establish new referral sources, our business, financial condition, and results of operations could be materially adversely affected.
- Changes to Medicare and Medicaid rates or methods governing Medicare and Medicaid payments for our services could materially adversely affect our business.
- Cost containment initiatives of third-party payors, including post-payment audits, could adversely impact our business, financial condition, and results of operations.
- The implementation of alternative payment models and the transition of Medicaid and Medicare beneficiaries to managed care organizations may limit our market share and could adversely affect our revenues.
- Changes in the case mix of patients, as well as payor mix and payment methodologies, and decisions and operations of third-party organizations may have a material adverse effect on our business, financial condition, and results of operations.
- Our business is reliant on federal and state spending, budget decisions, and continuous governmental operations which may fluctuate under different political conditions.
- Changes in drug utilization and/or pricing, PBM contracts, and Medicare Part D/Medicaid reimbursement may negatively impact our profitability.
- Changes in our relationships with pharmaceutical suppliers, including changes in drug availability or pricing, could adversely affect our business and financial results.
- Our business relies on the continual recruitment and retention of nurses, pharmacists, therapists, caregivers, direct support professionals, and other qualified personnel, including senior management.
- We are subject to federal, state, and local laws and regulations that govern our employment practices, including minimum wage, living wage, and paid time-off requirements. Failure to comply with these laws and regulations, or changes to these laws and regulations that increase our employment-related expenses, could adversely impact our operations.
The other 44 risks
- Our results of operations fluctuate on a quarterly basis.
- Our business may be harmed by labor relation matters.
- Because we are limited in our ability to control reimbursement rates received for our services, our business could be materially adversely affected if we are not able to maintain or reduce our costs to provide such services.
- Delays in collection or non-collection of our accounts receivable, particularly during the business integration process, could adversely affect our business, financial condition, and results of operations.
- If we fail to manage our growth effectively, we may be unable to execute our business plan, maintain high levels of service and satisfaction, or adequately address competitive challenges.
- Our growth strategy is partially dependent upon our ability to identify and successfully complete acquisitions, joint ventures, and other strategic initiatives, including the pending sale of our Community Living business, as well as organic growth. Any failure by us to manage or integrate acquisitions, divestitures, and other significant transactions successfully, or to organically grow our business, may have a material adverse effect on our business, financial condition, and results of operations.
- The sale of our Community Living business may not occur on the terms agreed to by the parties, in the expected time frame, or at all and, as a result, could adversely affect the Company’s business and financial condition.
- If we are unable to provide consistently high quality of care, our business will be adversely impacted.
- If we are unable to maintain our corporate reputation, or there is adverse publicity, including negative information on social media, or changes in public perception of our services, our business may suffer.
- If our existing customers do not continue with or renew their contracts with us, renew at lower fee levels, decline to purchase additional services from us or reduce the services received from us pursuant to those contracts, it could have a material adverse effect on our business, financial condition, and results of operations.
- Our business depends on our ability to effectively invest in, implement improvements to, and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems.
- Security breaches, loss of data, and other disruptions could compromise sensitive business or patient information, cause a loss of confidential patient data, employee data, personal information, or prevent access to critical information, and expose us to liability, litigation, and federal and state governmental inquiries and damage our reputation and brand.
- We are subject to risks related to credit card payments and other payment methods.
- We may be subject to substantial malpractice or other similar claims.
- We are exposed to various risks related to governmental inquiries, regulatory actions, and whistleblower and other lawsuits that could adversely affect our operating results. Our insurance may not cover all claims against us.
- Our current insurance program may expose us to unexpected costs and negatively affect our business, financial condition, and results of operations, particularly if we incur losses not covered by our insurance or if claims or losses differ from our estimates.
- Factors outside of our control, including those listed, have required, and could in the future require us to record an asset impairment of goodwill.
- Inclement weather, natural disasters, acts of terrorism, riots, civil insurrection or social unrest, looting, protests, strikes, or street demonstrations, or pandemics may impact our ability to provide services.
- We may be unable to adequately protect our intellectual property rights, which could harm our business.
- KKR Stockholder owns a significant portion of our stock, and its interests may conflict with yours in the future.
- Risks Related to Our Regulatory Framework
- We conduct business in a heavily regulated industry, and changes in regulations, the enforcement of these regulations, or violations of regulations may result in increased costs or sanctions that reduce our revenues and profitability.
- In the U.S., we conduct business in a heavily regulated industry and if we fail to comply with these laws and government regulations, we could incur fines and penalties or be required to make significant changes to our operations or experience adverse publicity, any or all of which could have a material adverse effect on our business, financial condition, and results of operations.
- Many states have Certificate of Need, or CON, laws or other regulatory provisions that may adversely impact our ability to expand into new markets and thereby limit our ability to grow and increase revenue.
- If we are unable to effectively adapt to changes in the healthcare industry, including changes to laws and regulations regarding or affecting U.S. healthcare reform, our business may be harmed.
- If we are found to have violated HIPAA, or any other applicable privacy and security laws and regulations, as well as contractual obligations, we could be subject to sanctions, fines, damages and other additional civil or criminal penalties, which could increase our liabilities, harm our reputation and have a material adverse effect on our business, financial condition and results of operations.
- We face and are currently subject to reviews, audits, and investigations under our licenses and/or contracts with federal and state government agencies and other payors, and these reviews, audits, and investigations could have adverse findings that may negatively impact our business.
- Quality reporting requirements may negatively impact Medicare reimbursement.
- Risks Related to Our Indebtedness
- Our high level of indebtedness requires that we dedicate a substantial portion of our cash flows to debt service payments and reduces the funds that would otherwise be available for other general corporate purposes and other business opportunities, which could adversely affect our operating performance, growth, profitability and financial condition, which in turn could make it more difficult for us to generate cash flow sufficient to satisfy all of our obligations under our indebtedness.
- Despite our high level of indebtedness, we may still be able to incur substantially more debt, which could further increase the risks to our financial condition described above.
- If we are unable to generate sufficient cash to service all of our indebtedness, we may be forced to take other actions to fund the satisfaction of our obligations under our indebtedness, which may not be successful.
- The terms of our outstanding indebtedness may restrict our current and future operations, particularly our ability to respond to changes or to take certain actions.
- Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase significantly.
- If the financial institutions that are lenders under the Revolving Credit Facility fail to extend credit under the facility or reduce the borrowing base, our liquidity and results of operations may be adversely affected.
- Our high level of indebtedness may hinder our ability to negotiate favorable terms with our suppliers, which could negatively impact our operating performance and, thus, could make it more difficult for us to generate cash flow sufficient to satisfy all of our obligations under our indebtedness.
- General Risk Factors
- We incur additional costs associated with the requirements of being a public company, and our management is required to devote substantial time to compliance adding complexity to running our business.
- Failure to comply with requirements to design, implement, and maintain effective internal controls could have a material adverse effect on our business and stock price.
- You may be diluted by the future issuance of additional common stock in connection with our incentive plans, acquisitions or otherwise.
- The Units may adversely affect the market price of our common stock.
- Our ability to raise capital in the future may be limited.
- Because we have no current plans to pay cash dividends on our common stock, you may not receive any return on investment unless you sell your common stock for a price greater than that which you paid for it.
- BrightSpring Health Services, Inc. depends on its subsidiaries for cash to fund its operations and expenses, including future dividend payments, if any, and to meet its debt obligations.
- Future sales or issuances, or the perception of future sales or issuances, by us or our existing stockholders, or the settlement of the purchase contracts, could cause the market price for our common stock to decline.
- Anti-takeover provisions in our organizational documents could delay or prevent a change of control.
- If tax laws change or we experience adverse outcomes resulting from examination of our tax returns or disagreements with taxing authorities, it could adversely affect our business, financial condition, and results of operations.
Legal proceedings
Legal Proceedings
See Note 15 "Commitments and Contingencies" within the audited consolidated financial statements and related notes included in this Annual Report on Form 10-K, which is incorporated herein by reference.
The opening of Item 3, Legal Proceedings.5
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2Yahoo FinanceBTSG quote
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARScott A. Greenwell, President
- 11SEC EDGARJennifer Yowler, President
- 12
- 13SEC EDGARJames F. Mattingly Jr., Officer
- 14
- 15SEC EDGARLisa A. Nalley, Officer
- 16SEC EDGARMichael A. McMaude, Officer
- 17SEC EDGARSteven S. Reed, Officer
- 18SEC EDGARNigam H. Shah, Board member
- 19SEC EDGARHunter H. Craig, Board member
- 20SEC EDGARMatthew Dambrosio, Board member
- 21SEC EDGARMax Lin, Board member
- 22SEC EDGAROlivia F. Kirtley, Board member
- 23SEC EDGARTimothy A. Wicks, Board member
- 24
- 25SEC EDGARResults of operations
- 26
- 27SEC EDGAREntered a material agreement
- 28SEC EDGARShareholder vote
- 29SEC EDGARResults of operations
- 30
- 31SEC EDGAREntered a material agreement
- 32SEC EDGARResults of operations
- 33SEC EDGARResults of operations
- 34SEC EDGAREntered a material agreement
- 35SEC EDGARResults of operations
- 36SEC EDGARResults of operations
- 37NasdaqNasdaq calendar
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49